Description:

This lecture will outline and describe the current understanding of thyroid eye disease (TED) and its interrelation with Graves' Disease.  It will describe incidence, risk factors, and associated systemic signs, symptoms, and pathophysiology including Rundle's curve.  We will discuss treatment options for TED including the recent FDA approval of Teprotumumab, its clinical trials, study endpoints, and adverse reactions.  Masquerading ocular findings that may be early signs of TED will be described as well as lab testing that can help with the early detection of TED will be discussed.  Doctors have a knowledge need for this practice gap which means having the knowledge of how to detect, diagnose, and treat TED in an integrated, multidisciplinary method.

Course Code:

AOA255-SD

Speaker(s):

Jacob Lang, O.D.
drjakelang@gmail.com

Selina McGee, O.D.
drmcgee@bespokevision.org

Credits:

1

AOA Expiration Date:

4/20/2025

Related News

What optometry’s advocates are championing at AOA on Capitol Hill

Learn about the priority federal issues that hundreds of optometrists and optometry students will take to Capitol Hill as part of optometry’s single-largest annual advocacy gathering, April 14-16, and how you can join.

Representation matters in optometry

Although about 13% of the U.S. population is Black, they are woefully underrepresented in optometry. They represent about 2% of practicing doctors of optometry and a little over 3% of full-time students in optometry schools and colleges, according to studies. Black doctors of optometry seek to grow those numbers.

Making blurry vision clear

February is Low Vision Awareness Month. Take note of considerations for enhancing success with near magnification.